CAR T-cell therapy represents one of the most significant advances in blood cancer treatment in recent decades. It is a form of immunotherapy that harnesses the patient's own immune system to recognize and destroy cancer cells. CAR stands for Chimeric Antigen Receptor — a synthetic receptor engineered in the laboratory and added to a patient's T-cells to give them the ability to target specific cancer cells.
The process begins with leukapheresis — collecting T-cells from the patient's blood. These T-cells are then sent to a specialized laboratory where they are genetically modified to express the chimeric antigen receptor on their surface. The modified cells are multiplied to produce millions of CAR T-cells, which are then infused back into the patient. Once in the body, these engineered cells seek out and destroy cancer cells bearing the target antigen.
CAR T-cell therapy has shown remarkable results in certain blood cancers. It is currently approved for specific types of B-cell Non-Hodgkin Lymphoma that have relapsed or not responded to prior treatments, certain cases of Acute Lymphoblastic Leukemia (ALL) in children and young adults, and more recently, for relapsed or refractory Multiple Myeloma. In some patients who had exhausted all other treatment options, CAR T-cell therapy has achieved complete and durable remissions.
Despite its promise, CAR T-cell therapy carries significant side effects that require specialized management. Cytokine Release Syndrome (CRS) is the most common — it occurs when the activated CAR T-cells release large amounts of inflammatory molecules, causing fever, low blood pressure, and in severe cases, organ dysfunction. Neurotoxicity, known as Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), can cause confusion, seizures, and other neurological symptoms. Both complications are usually manageable when treated at experienced centres.
The therapy is currently available only at specialized treatment centres equipped to manage these side effects. The manufacturing process takes 3-4 weeks, during which patients may need bridging therapy to control their disease. Not all patients are eligible — candidates must have adequate organ function and a sufficient number of healthy T-cells for collection.
Research is rapidly expanding the applications of CAR T-cell therapy. Clinical trials are investigating its use in additional blood cancers, earlier lines of treatment (not just relapsed disease), and even some solid tumours. Next-generation CAR T-cells are being developed to be more effective, safer, and potentially available as off-the-shelf products that do not require individualized manufacturing.
For patients with relapsed or refractory blood cancers, CAR T-cell therapy offers hope where conventional treatments have failed. If you or a loved one is considering this therapy, discuss eligibility with your hematologist and seek referral to a centre with experience in administering CAR T-cell treatment.